Meridica has announced the renewal of its showcasing agreement for Xcelodose, its powder micro-dosing technology, with pharmaceutical services organisation Quintiles
Meridica has announced the renewal of its showcasing agreement for Xcelodose, its powder micro-dosing technology, with pharmaceutical services organisation Quintiles.
The showcasing agreement, which has already been in place for over a year, makes an Xcelodose system available to Quintiles's customers in Quintiles's GMP facilities at Edinburgh, UK, as well as providing the framework for co-promotion of the Xcelodose technology to the pharmaceutical industry.
Quintiles currently features Xcelodose as a unique technology, which has enabled the company to offer its customers micro-dosing of pharmaceutical drug powder for use in oral dose and inhaled dose clinical supplies.
The Xcelodose technology has a number of substantial business benefits, including potentially shortening the drug development process, by reducing the need for costly stability studies, and the avoidance of laborious hand-filling of capsules. Phil Woodhead, Quintiles's VP pharmaceutical sciences Europe, said: "The successful showcasing agreement with Meridica has enabled us to offer the innovative Xcelodose technology to the marketplace.
"This has clearly fulfilled an unmet market need as, since its installation in May 2002, it has been in constant demand by pharmaceutical companies.
"We are pleased to extend this agreement with Meridica and our investment in the Xcelodose system serves to reinforce Quintiles's commitment to providing innovative technologies to its clients".
David Edwards, Meridica's director of strategic marketing, said: "As the world's largest pharmaceutical services organisation, Quintiles provides a major endorsement of the value of our Xcelodose technology to the pharmaceutical industry.
"We are delighted to continue our relationship, which we believe has been mutually beneficial. "We believe the relationship has worked extremely well at all levels between Meridica and Quintiles and look forward to continuing success in developing this market."
